T. Rowe Price Health Sciences Fund (PRHSX)
| Fund Assets | 11.80B |
| Expense Ratio | 0.80% |
| Min. Investment | $500,000 |
| Turnover | 52.40% |
| Dividend (ttm) | 10.10 |
| Dividend Yield | 12.29% |
| Dividend Growth | -1.44% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 15, 2025 |
| Previous Close | 81.65 |
| YTD Return | -1.80% |
| 1-Year Return | 10.91% |
| 5-Year Return | 3.98% |
| 52-Week Low | 64.18 |
| 52-Week High | 86.25 |
| Beta (5Y) | 0.72 |
| Holdings | 139 |
| Inception Date | Dec 29, 1995 |
About PRHSX
T. Rowe Price Health Sciences Fund is an actively managed mutual fund focused on the health sciences sector. Its primary objective is to achieve long-term capital appreciation by investing at least 80% of its net assets in the common stocks of companies involved in health care, medicine, or life sciences. The fund’s investment universe spans pharmaceuticals, biotechnology, medical device manufacturers, and health care service providers, targeting both large- and mid-capitalization firms. The fund’s holdings are diversified across key players in the health care industry, with significant allocations to leading names such as Eli Lilly and UnitedHealth Group. This approach allows the fund to capture growth opportunities driven by medical innovation, demographic trends, and advances in health technologies. It typically maintains a concentrated portfolio, with the top ten holdings representing a substantial portion of total assets, emphasizing the manager’s high-conviction ideas. With an inception dating back to 1995, the fund has established itself as a notable vehicle for investors seeking specialized exposure to the health care sector. It plays a significant role in the market by offering focused access to a defensive and innovative segment of the global economy, making it a reference point among sector-specific mutual funds.
Performance
PRHSX had a total return of 10.91% in the past year, including dividends. Since the fund's inception, the average annual return has been 17.86%.
Other Share Classes
These are alternative share classes of the same fund, from the same provider.
| Symbol | Share Class | Expense Ratio |
|---|---|---|
| THISX | T. Rowe Price Health Sciences Fund-i Class | 0.67% |
Top 10 Holdings
49.07% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.37% |
| Aggregate Miscellaneous Equity | n/a | 8.98% |
| Intuitive Surgical, Inc. | ISRG | 4.47% |
| Thermo Fisher Scientific Inc. | TMO | 4.27% |
| argenx SE | ARGX | 3.87% |
| Stryker Corporation | SYK | 3.51% |
| UnitedHealth Group Incorporated | UNH | 3.29% |
| AstraZeneca PLC | AZN | 2.83% |
| AbbVie Inc. | ABBV | 2.75% |
| Danaher Corporation | DHR | 2.72% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 15, 2025 | $10.1023 | Dec 16, 2025 |
| Dec 16, 2024 | $10.2497 | Dec 17, 2024 |
| Dec 15, 2023 | $4.578 | Dec 18, 2023 |
| Dec 15, 2022 | $1.5867 | Dec 16, 2022 |
| Dec 15, 2020 | $0.930 | Dec 16, 2020 |
| Dec 16, 2019 | $5.030 | Dec 17, 2019 |